Lactoferricin B
Lactoferricin B is a ferociously potent antimicrobial peptide sheared directly from the core of bovine lactoferrin via gastric pepsin cleavage. It exists as a massively concentrated, biologically active fragment that possesses significantly higher pathogenic lethality than its parent protein. It is aggressively evaluated for extreme broad-spectrum annihilation of resistant bacteria, invasive fungi, and select malignant tumor lines.
Quick Stats
Scientific Data
Mechanism of Action
Lactoferricin B (LfcinB) is a cationic antimicrobial peptide derived from bovine lactoferrin through pepsin digestion. It is an amphipathic peptide (amino acids 17-41 of bovine lactoferrin) that kills bacteria by disrupting negatively charged microbial membranes. Unlike many AMPs, LfcinB also shows anticancer activity — it induces apoptosis in tumour cells via ROS generation and mitochondrial pathway activation. Additionally, it binds lipopolysaccharide (LPS) to neutralize endotoxin activity, providing anti-inflammatory effects in sepsis models.
Source: PMID: 18721608
Dosing Protocol
| Typical Dose | 50-250 mcg (research) |
| Frequency | Per study protocol |
| Half-Life | ~1-2 hours (estimated) |
| Common Vial Sizes | 5 mg |
Dosing Protocols
In vitro / Animal
Body-Weight Dosing Reference
Estimated doses extrapolated from the published research range of 50–250 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.
| Weight | Low Dose | Target Dose | High Dose |
|---|---|---|---|
| 120 lb(54 kg) | 39 mcg | 116 mcg | 193 mcg |
| 140 lb(63 kg) | 45 mcg | 135 mcg | 225 mcg |
| 160 lb(73 kg) | 52 mcg | 156 mcg | 261 mcg |
| 180 lb(82 kg) | 59 mcg | 176 mcg | 293 mcg |
| 200 lb(91 kg) | 65 mcg | 195 mcg | 325 mcg |
| 220 lb(100 kg) | 71 mcg | 214 mcg | 357 mcg |
| 250 lb(113 kg) | 81 mcg | 242 mcg | 404 mcg |
💉 For exact syringe units based on your vial concentration, use the Lactoferricin B Reconstitution Calculator →
Administration
Expected Timeline
Who Is It For?
Antimicrobial Research
EmergingBroad-spectrum activity including antibiotic-resistant pathogens (MRSA, Pseudomonas).
Anticancer (Preclinical)
EmergingInduces apoptosis in colon, breast, and leukemia cell lines in vitro.
Reconstitution Example
Safety & Considerations
Research compound only. No human clinical trials at therapeutic doses. Derived from bovine lactoferrin — avoid in dairy protein allergy. Cytotoxic at high concentrations.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Dosing Quick Reference
Frequently Asked Questions
Is lactoferricin B the same as lactoferrin?▼
References
- Bellamy W et al. “"Lactoferricin B: a new antibacterial peptide from bovine lactoferrin".” Biochimica et Biophysica Acta (1992). PMID: 1310476
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code